BioStem Technologies Q3 revenue falls year over year 

By Reuters News


Overview

  • US regenerative medicine firm's Q3 revenue fell yr/yr, with hospital revenue up sequentially

  • Company raised full-year 2026 revenue guidance

  • Cost reduction plan expected to lower annualized cash operating expenses by $10-$12 mln from 2027


Outlook

  • BioStem raises 2026 revenue guidance to $28 mln-$29 mln from $26 mln-$29 mln

  • Company expects in-house production of Neox and Clarix to begin in H1 2027

  • BioStem finalizing cost reduction plan to cut annualized cash operating expenses by $10 mln-$12 mln, with full benefit in Q1 2027


Result Drivers

  • CUSTOMER EXPANSION - Co said sequential hospital revenue growth was driven by adding new accounts and deeper penetration with existing customers

  • HIGHER SUPPLY COSTS - Co said gross margin fell sequentially due to higher pricing under BioTissue supply agreement after discounted pricing expired

  • OPERATING COST INCREASES - Co said operating expenses rose mainly due to higher general and administrative costs related to uplisting, financing activity, and payroll taxes on RSU vesting


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$7.64 mln

$7.17 mln (1 Analyst)

Q3 Loss Per Share

$0.64

$0.43 (1 Analyst)

Q3 Net Loss

$11.40 mln

$9.45 mln (1 Analyst)


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • Wall Street's median 12-month price target for BioStem Technologies, Inc. is $7.00, about 376.2% above its November 11 closing price of $1.47


Reuters Recommended Reads

  • Nov 12 - EyePoint Pharmaceuticals Q3 revenue falls, net loss widens

  • Nov 12 - Pelthos Q3 Zelsuvmi revenue jumps 114%, net loss narrows

  • Nov 12 - Fennec Pharma Q3 product sales rise 56% on PEDMARK demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.